Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Breast Neoplasms | 10 | 2024 | 154 | 4.660 |
Why?
|
Breast Neoplasms | 35 | 2024 | 21156 | 2.180 |
Why?
|
BRCA2 Protein | 9 | 2024 | 802 | 1.590 |
Why?
|
BRCA1 Protein | 9 | 2024 | 1158 | 1.410 |
Why?
|
Receptor, erbB-2 | 10 | 2024 | 2586 | 1.380 |
Why?
|
Paclitaxel | 3 | 2024 | 1737 | 0.990 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 11843 | 0.930 |
Why?
|
Neoadjuvant Therapy | 13 | 2024 | 2896 | 0.870 |
Why?
|
Pyrazoles | 2 | 2024 | 2024 | 0.780 |
Why?
|
Nitriles | 2 | 2024 | 984 | 0.740 |
Why?
|
Ovarian Neoplasms | 4 | 2023 | 4906 | 0.700 |
Why?
|
Platinum | 1 | 2021 | 222 | 0.660 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13708 | 0.640 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2019 | 2145 | 0.550 |
Why?
|
Anthracyclines | 3 | 2020 | 286 | 0.520 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2017 | 330 | 0.520 |
Why?
|
Neutropenia | 1 | 2021 | 892 | 0.510 |
Why?
|
Camptothecin | 3 | 2024 | 594 | 0.490 |
Why?
|
Immunoconjugates | 4 | 2024 | 968 | 0.490 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 1518 | 0.480 |
Why?
|
Pyrimidines | 2 | 2024 | 3050 | 0.460 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 928 | 0.450 |
Why?
|
Medically Underserved Area | 1 | 2015 | 266 | 0.430 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 1244 | 0.420 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2834 | 0.420 |
Why?
|
Genes, BRCA2 | 1 | 2015 | 592 | 0.400 |
Why?
|
Genes, BRCA1 | 1 | 2015 | 755 | 0.380 |
Why?
|
Female | 51 | 2024 | 396943 | 0.350 |
Why?
|
Vulnerable Populations | 1 | 2015 | 717 | 0.340 |
Why?
|
Troponin I | 2 | 2017 | 662 | 0.330 |
Why?
|
Genetic Testing | 4 | 2024 | 3586 | 0.330 |
Why?
|
Troponin T | 2 | 2017 | 787 | 0.310 |
Why?
|
Patient Selection | 3 | 2021 | 4266 | 0.310 |
Why?
|
Humans | 61 | 2024 | 768451 | 0.290 |
Why?
|
Maytansine | 2 | 2019 | 88 | 0.290 |
Why?
|
Urban Population | 1 | 2015 | 2047 | 0.280 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2022 | 352 | 0.280 |
Why?
|
Ovariectomy | 2 | 2020 | 614 | 0.260 |
Why?
|
Population Surveillance | 1 | 2015 | 2601 | 0.240 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9425 | 0.210 |
Why?
|
Neoplasms | 4 | 2024 | 22386 | 0.210 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9182 | 0.200 |
Why?
|
Lymphoma | 1 | 2011 | 1907 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5709 | 0.190 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2062 | 0.190 |
Why?
|
Mutation | 7 | 2022 | 30243 | 0.190 |
Why?
|
Maximum Tolerated Dose | 2 | 2024 | 890 | 0.190 |
Why?
|
Weight Gain | 1 | 2011 | 2357 | 0.190 |
Why?
|
Omeprazole | 1 | 2021 | 106 | 0.180 |
Why?
|
Survivors | 1 | 2011 | 2381 | 0.180 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 427 | 0.180 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11249 | 0.180 |
Why?
|
Phthalazines | 1 | 2023 | 396 | 0.180 |
Why?
|
Receptors, Estrogen | 3 | 2022 | 2243 | 0.170 |
Why?
|
Middle Aged | 24 | 2024 | 223418 | 0.170 |
Why?
|
Urogenital System | 1 | 2019 | 88 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 18048 | 0.160 |
Why?
|
Lisinopril | 1 | 2019 | 60 | 0.160 |
Why?
|
Piperazines | 2 | 2021 | 2546 | 0.160 |
Why?
|
Prognosis | 4 | 2023 | 30028 | 0.160 |
Why?
|
Treatment Outcome | 9 | 2024 | 65409 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2022 | 564 | 0.150 |
Why?
|
Estrogen Receptor alpha | 1 | 2022 | 582 | 0.150 |
Why?
|
Germ-Line Mutation | 2 | 2024 | 1884 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 647 | 0.150 |
Why?
|
Carboplatin | 1 | 2021 | 798 | 0.150 |
Why?
|
Pyridines | 2 | 2021 | 2888 | 0.150 |
Why?
|
Cardiac Imaging Techniques | 1 | 2020 | 281 | 0.150 |
Why?
|
Adult | 19 | 2024 | 223542 | 0.140 |
Why?
|
Brain | 1 | 2024 | 27438 | 0.140 |
Why?
|
Aged | 14 | 2024 | 171520 | 0.140 |
Why?
|
Lymphedema | 1 | 2023 | 527 | 0.140 |
Why?
|
Genetic Counseling | 2 | 2023 | 633 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2020 | 679 | 0.130 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 300 | 0.130 |
Why?
|
District of Columbia | 1 | 2015 | 159 | 0.120 |
Why?
|
Central Nervous System | 1 | 2022 | 1348 | 0.120 |
Why?
|
Cell Adhesion Molecules | 1 | 2021 | 1615 | 0.120 |
Why?
|
Purines | 1 | 2018 | 614 | 0.120 |
Why?
|
Retrospective Studies | 7 | 2024 | 81834 | 0.120 |
Why?
|
Mastectomy | 1 | 2023 | 1852 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1062 | 0.120 |
Why?
|
Jews | 1 | 2016 | 358 | 0.120 |
Why?
|
Genetic Heterogeneity | 1 | 2018 | 738 | 0.120 |
Why?
|
Aminopyridines | 1 | 2018 | 578 | 0.110 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 2046 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2024 | 4931 | 0.110 |
Why?
|
Breast | 1 | 2023 | 1976 | 0.110 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1382 | 0.110 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2643 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2024 | 3234 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 958 | 0.110 |
Why?
|
RNA | 1 | 2023 | 2727 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2018 | 864 | 0.100 |
Why?
|
Estrogens | 1 | 2019 | 1531 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4049 | 0.100 |
Why?
|
Aged, 80 and over | 7 | 2024 | 59680 | 0.100 |
Why?
|
Developing Countries | 1 | 2024 | 2901 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2024 | 10784 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2024 | 5342 | 0.100 |
Why?
|
Time Factors | 5 | 2021 | 40271 | 0.090 |
Why?
|
Radiation Injuries | 1 | 2019 | 1205 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2023 | 3550 | 0.090 |
Why?
|
Obesity | 2 | 2023 | 13065 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6856 | 0.090 |
Why?
|
Carrier Proteins | 1 | 2024 | 4948 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3939 | 0.090 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 3941 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2659 | 0.080 |
Why?
|
Germ Cells | 2 | 2024 | 641 | 0.080 |
Why?
|
Cytokines | 1 | 2024 | 7449 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 1120 | 0.080 |
Why?
|
Hippocratic Oath | 1 | 2008 | 16 | 0.080 |
Why?
|
Young Adult | 6 | 2020 | 60045 | 0.080 |
Why?
|
Neoplasm, Residual | 2 | 2024 | 1014 | 0.070 |
Why?
|
Heart Diseases | 1 | 2020 | 2816 | 0.070 |
Why?
|
DNA Repair | 1 | 2016 | 2051 | 0.070 |
Why?
|
Pilot Projects | 1 | 2019 | 8730 | 0.060 |
Why?
|
Drug Approval | 1 | 2012 | 817 | 0.060 |
Why?
|
Antigens, Neoplasm | 2 | 2023 | 2003 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 5043 | 0.060 |
Why?
|
Heart Failure | 1 | 2008 | 11857 | 0.060 |
Why?
|
Incidence | 1 | 2022 | 21552 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9642 | 0.060 |
Why?
|
Neuropilin-1 | 1 | 2024 | 90 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4451 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3611 | 0.050 |
Why?
|
Registries | 2 | 2020 | 8373 | 0.050 |
Why?
|
Pamphlets | 1 | 2023 | 71 | 0.050 |
Why?
|
Risk Assessment | 4 | 2024 | 24311 | 0.050 |
Why?
|
Age Factors | 3 | 2017 | 18478 | 0.050 |
Why?
|
Risk Factors | 6 | 2023 | 74915 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 631 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9507 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2023 | 354 | 0.050 |
Why?
|
Axilla | 1 | 2023 | 629 | 0.050 |
Why?
|
Body Weight | 1 | 2011 | 4630 | 0.050 |
Why?
|
Animals | 4 | 2024 | 169418 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 54914 | 0.040 |
Why?
|
Genomics | 1 | 2016 | 5909 | 0.040 |
Why?
|
Stroke Volume | 3 | 2021 | 5620 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3708 | 0.040 |
Why?
|
Telephone | 1 | 2023 | 630 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15880 | 0.040 |
Why?
|
Administration, Intravaginal | 1 | 2019 | 149 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 669 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 743 | 0.040 |
Why?
|
Comprehension | 1 | 2024 | 641 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 467 | 0.040 |
Why?
|
Aromatase Inhibitors | 1 | 2022 | 518 | 0.040 |
Why?
|
Sex Factors | 1 | 2011 | 10647 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3665 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 2023 | 1276 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2020 | 467 | 0.030 |
Why?
|
Logistic Models | 1 | 2011 | 13324 | 0.030 |
Why?
|
Quality of Life | 2 | 2022 | 13497 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2024 | 1357 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2022 | 1084 | 0.030 |
Why?
|
United States | 3 | 2020 | 73121 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1320 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3281 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1196 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1909 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15460 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2339 | 0.030 |
Why?
|
Atrophy | 1 | 2019 | 1648 | 0.030 |
Why?
|
Body Mass Index | 1 | 2011 | 13030 | 0.030 |
Why?
|
Gynecology | 1 | 2019 | 532 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14728 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15638 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 89168 | 0.030 |
Why?
|
Male | 4 | 2024 | 364781 | 0.030 |
Why?
|
Radiotherapy | 1 | 2019 | 1510 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2019 | 2437 | 0.020 |
Why?
|
Qualitative Research | 1 | 2022 | 3115 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2461 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2020 | 2819 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4120 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2302 | 0.020 |
Why?
|
Doxorubicin | 1 | 2016 | 2229 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2594 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10125 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4728 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 17149 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10358 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6537 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1876 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2190 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9687 | 0.010 |
Why?
|
Databases, Factual | 1 | 2020 | 8081 | 0.010 |
Why?
|
Recurrence | 1 | 2017 | 8510 | 0.010 |
Why?
|
Physicians | 1 | 2019 | 4615 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39430 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26351 | 0.010 |
Why?
|
Mice | 1 | 2024 | 82045 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 41797 | 0.010 |
Why?
|
Concepts
(196)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(60)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_